GBSN
| eröffnet am: | 19.09.16 19:11 von: | Gerd Geldhai |
| neuester Beitrag: | 15.07.17 07:42 von: | CentTrader |
| Anzahl Beiträge: | 1062 | |
| Leser gesamt: | 125647 | |
| davon Heute: | 18 | |
bewertet mit 3 Sternen |
||
|
|
||
19.09.16 19:11
#1
Gerd Geldhai
GBSN
Die erste Rakete, die in Lichtgeschwindigkeit rückwärts fliegen kann.
1036 Postings ausgeblendet.
23.05.17 07:26
#1042
CentTrader
Epigenomics hab ich nicht so verfolgt, aber GBSN
bewegt sich momentan nach vielen RS in ATL-Nähe (0,75 USD) und man kann entweder auf einen nachhaltigen Turnaround spekulieren (schwierig) oder wieder mal auf einen kurzfristigen Spike aus dem Stand von 100 bis mehreren 100 Prozent, wofür GBSN bekannt ist. (Keine Kauf- oder Verkaufempfehlung, sondern eine Schilderung der momentanen Lage und Beobachtungen aus der Vergangenheit.)
05.07.17 16:42
#1047
CentTrader
Paar interessante Research-Links zu GBSN
https://finance.yahoo.com/news/...ntific-130000293.html?.tsrc=applewf
Angebliches PriceTarget 1$ innerhalb 12 Monaten
Quelle direkt:
http://irdirect.net/prviewer/release/id/2577843
Stammt von hier:
http://www.seethruequity.com/news/
Ob die das ernst meinen?
Angebliches PriceTarget 1$ innerhalb 12 Monaten
Quelle direkt:
http://irdirect.net/prviewer/release/id/2577843
Stammt von hier:
http://www.seethruequity.com/news/
Ob die das ernst meinen?
05.07.17 20:10
#1048
CentTrader
Auch auf der GBSN-Website:
"Seethru Equity Issues Update Report on GBSN
posted on July 5, 2017 in Featured, In the News, Investors
On July 5, 2017, Seethru Equity issued a press release regarding an update to their 2015 research report on Great Basin. The press release discusses the Company’s expanded menu, growing sales funnel, and sets a new price target."
http://gbscience.com/seethru-equity-issues-update-report-gbsn/
posted on July 5, 2017 in Featured, In the News, Investors
On July 5, 2017, Seethru Equity issued a press release regarding an update to their 2015 research report on Great Basin. The press release discusses the Company’s expanded menu, growing sales funnel, and sets a new price target."
http://gbscience.com/seethru-equity-issues-update-report-gbsn/
07.07.17 16:41
#1051
CentTrader
Unternehmenspräsentation GBSN 7.7.2017
http://gbscience.com/investor-presentation/
Investor Presentation
posted on July 7, 2017 in Featured, Investors
GBSN Investor Deck – July 2017_FINAL
http://gbscience.com/wp-content/uploads/...eck-July-2017_FINAL-1.pptx
Investor Presentation
posted on July 7, 2017 in Featured, Investors
GBSN Investor Deck – July 2017_FINAL
http://gbscience.com/wp-content/uploads/...eck-July-2017_FINAL-1.pptx
07.07.17 22:23
#1053
CentTrader
PDF-Link Präsentation
Scott Gordon von GBSN hat geantwortet: "Better if it is a pdf. For sure."
Hier der PDF-Link für die heutige Präsentation:
http://gbscience.com/wp-content/uploads/...r-Deck-July-2017_FINAL.pdf
Ist jetzt auch so auf der Website aufrufbar.
Hier der PDF-Link für die heutige Präsentation:
http://gbscience.com/wp-content/uploads/...r-Deck-July-2017_FINAL.pdf
Ist jetzt auch so auf der Website aufrufbar.
08.07.17 00:03
#1054
CentTrader
Seite 20 in der PDF-Präsentation:
Capital Structure
▪ Common shares & equivalents outstanding–11.6MM (incl. shares from Series K Warrants)
▪ No variable priced instruments
▪ $20.3 million Series A Convertible Note
▪ Convertible at $3.00 a share, no resets or variable rate conversions, 6.8 million shares
▪ Not convertible for 6 months from issuance (April 17, 2017)
▪ Other debt of $1.8MM, including $0.1MM Series B Convertible Note, convertible at $1.10
▪ Enterprise value of approximately $26.7MM
▪ Series J warrants are exercisable into 22.4MM shares until August 21, 2017
▪ Exercise price of $0.30 (subject to adjustment by the Company)
▪ Common shares & equivalents outstanding–11.6MM (incl. shares from Series K Warrants)
▪ No variable priced instruments
▪ $20.3 million Series A Convertible Note
▪ Convertible at $3.00 a share, no resets or variable rate conversions, 6.8 million shares
▪ Not convertible for 6 months from issuance (April 17, 2017)
▪ Other debt of $1.8MM, including $0.1MM Series B Convertible Note, convertible at $1.10
▪ Enterprise value of approximately $26.7MM
▪ Series J warrants are exercisable into 22.4MM shares until August 21, 2017
▪ Exercise price of $0.30 (subject to adjustment by the Company)
10.07.17 15:02
#1055
CentTrader
Meine Ansichten bezüglich GBSN
haben sich seit der Veröffentlichung der Präsentation am Freitag etwas verbessert.
Artikel:
http://www.finanznachrichten.de/...gangenheit-gesunde-zukunft-620.htm
Artikel:
http://www.finanznachrichten.de/...gangenheit-gesunde-zukunft-620.htm
13.07.17 13:10
#1056
CentTrader
Erfolgsmeldung:
Great Basin Scientific Receives FDA 510(k) Clearance for Stool Bacterial Pathogens Panel
http://globenewswire.com/news-release/2017/07/13/...hogens-Panel.html
http://globenewswire.com/news-release/2017/07/13/...hogens-Panel.html
13.07.17 14:43
#1057
CentTrader
Zitate aus der Meldung #1056
"...These evaluations alone represent the potential for nearly $2.0 million in annual revenue for the Company, which historically has had an 82% win rate for its product evaluations. With this FDA clearance, the Company will begin to actively market SBPP to its current customer base of over 230 hospitals and labs, and will commence aggressive outreach to potential new customers. Sites that have evaluated and are ready to adopt the panel can now purchase kits to report patient results. ..."
"...As announced in the Company’s Business Update on June 26, 2017, the Company had approximately $5.0 million of potential new revenues in the new business pipeline, of which SBPP comprises nearly $2.0 million. These potential revenue estimates, as well as those below are based on the evaluating site’s own estimate of their expected testing volumes multiplied by the product price offered to the prospective customer. ..."
"...As announced in the Company’s Business Update on June 26, 2017, the Company had approximately $5.0 million of potential new revenues in the new business pipeline, of which SBPP comprises nearly $2.0 million. These potential revenue estimates, as well as those below are based on the evaluating site’s own estimate of their expected testing volumes multiplied by the product price offered to the prospective customer. ..."
14.07.17 22:05
#1061
CentTrader
Gestern nach der Meldung zu Beginn Kurse bis 0.50
......
Weiterlesen im Thread
http://www.ariva.de/forum/...kaufkurse-547917?new_pnr=23017013#bottom
Beitrag #6
Hab mich schon gewundert, daß hier außer mir keiner gepostet hat. Hab hier aus alter Gewohnheit weitergeschrieben, ohne den neuen Thread zu bemerken.
Weiterlesen im Thread
http://www.ariva.de/forum/...kaufkurse-547917?new_pnr=23017013#bottom
Beitrag #6
Hab mich schon gewundert, daß hier außer mir keiner gepostet hat. Hab hier aus alter Gewohnheit weitergeschrieben, ohne den neuen Thread zu bemerken.
15.07.17 07:42
#1062
CentTrader
Weiter gehts nun im neuen GBSN-Thread:
http://www.ariva.de/forum/...auf-nun-kaufkurse-547917?page=0#jumppos5

